Introduction
HumanT-lymphotropic virus type I (HTLV-I)-associated myelopathy (HAM)is a chronic progressive neurological disorder characterized by bilateral pyramidal tract involvement and sphincteric disturbances ( 1) . Various treatment modalities, including corticosteroids (2), interferon-a (3) and plasmapheresis (4) , have proven to be limited or dubious benefit. Recently, we reported the efficacy of pentoxifylline (PTX) treatment in patients with HAM (5) . Although PTXdownregulates inflammatory cytokine production, such as tumor necrosis factor-alpha (TNF-oc), interferon-gamma (IFN-y) and granulocytemacrophage colony stimulating factor (GM-CSF), in peripheral blood mononuclear cells of HAMpatients (6) , the precise mechanismsby which PTXserves to ameliorate the motor dis-ability in HAMare far from clear. Recent studies indicate that T helper lymphocytes can be divided into two distinct populations based on the patterns of specific cytokines synthesized: T helper type 1 (Thl), which induces cell-mediated immunity, produces interleukin-2 (IL-2) and IFN-y, whereas T helper type 2 (Th2), which induces humoral immunity, produces interleukin-4 and -10 (IL-4 and IL-10) (7, 8) . For differentiation to Thl , IFN-y and interleukin-12 (IL-12), which is mainly derived from antigen-presenting cells, are vitally important cytokines (9, 10) . On the other hand, for differentiation to Th2, IL-4 is required (ll). Imbalances between Thl and Th2 cytokine responses appear to play a significant role in the pathogenesis of autoimmune or inflammatory diseases (12) (13) (14) . In previous studies, we demonstrated that spontaneous production of inflammatory cytokines, such as IFN-y, TNF-oc and GM-CSF, but not IL-4, was simultaneously increased in cultured CD4+T cells of HAMpatients (15) . Very recently, we demonstrated that both the serum and cerebrospinal fluid (CSF) level of IFN-y are elevated in HAM patients with elevated levels of serum IL-12, compared to patients with other neurological diseases including anti-HTLV-Iseropositive carriers (16) . These data suggested that the Thl rather than Th2 cell population was dominant in peripheral blood CD4+ T lymphocytes of HAMpatients. In the present study, we employed a sensitive enzymeimmunoassay to measure IFN-y as a Thl cytokine, and IL-4 and IL-10 as Th2 cytokines in sera and CSF of HAMpatients before and after PTXtreatment to ascertain whether changes in Thl and Th2 cytokine levels could account for the clinical improvement following PTXtherapy.
Patients and Methods
Patients and treatment protocol
Twelve HAMpatients (2 men and 10 women; mean age, 55 years; age range, 34-72 years), with a mean duration of illness of 10 years (range, 2-24 years), were studied. The diagnosis of HAMwas based on previously described criteria (17) . None of the patients had undergone plasmapheresis or were treated with immunomodulatory drugs, such as corticosteroid and interferon-a, or with anti-spastic drugs. All patients gave informed consent. Motor disability scores were rated from 0 to 10, according to a previously described rating scale (4) . Complete clinical profiles of 6 of the 12 HAMpatients and the treatment protocol have been previously described (5) . Briefly, 300 mg of PTX (Hoechst Japan, Tokyo) was administered daily by the oral route to HAMpatients for 4 weeks. Prior to starting treatment, patients were instructed to walk a 10-mdistance and attained a fairly constant walking time. Rehabilitation programs in all HAM patients were the same.
Assessment of clinical effect
In evaluating the clinical efficacy of PTX treament, we assessed the changes in motor disability scores, the degree of spasticity on neurological examination, and the time required to walk 10 m before and after PTXtreatment. The change of spasticity was objectively evaluated by the same neurologist before and after this treatment.
Sampleprepara tion
Blood samples, collected before and after PTXtreatment, were allowed to clot at room temperature for 60 minutes, and sera were separated by centrifugation. CSFsamples were obtained by lumbar puncture and were centrifuged to remove cells. Serum and CSF were rapidly frozen and stored at -80°C until use. 
Measurement of TMand Th2 cytokines

Results
Changes in Th1 and Th2 cytokine levels in sera and CSFafter PTXtreatment As shown in Fig. 1A , PTXtreatment induced a decremental reduction in serum IFN-ylevels in 6 of 12 HAMpatients, whereas IL-4 and IL-10 levels increased in the sera of 6 and 5 HAMpatients, respectively, after PTX treatment. Amongthese patients, IL-4 and IL-10 increased from undetectable to detectable levels in 3 and 4 HAMpatients, respectively. On the other hand, as shown in Fig. IB , IFN-ylevels in CSFdecreased in 3 of 7 HAMpatients after PTXtreatment. Both IL-4 and IL-10 levels in CSF increased in 4 of7 HAMpatients.
Relationship between the efficacy of PTXtreatment and elevation of serum Th2 cytokine levels
To ascertain whether or not the elevation in the serum Th2 cytokine level was correlated with clinical improvement, we compared the efficacy of PTXtreatment in patients with (group 1) and without (group 2) elevated Th2 cytokine levels in sera.
In group 1, all HAMpatients had elevated levels of both IL-4 and IL-10 except for case 6 who only had an elevated level of IL-4. As shownin Table 1 , the motor disability scores were dramatically improved in 3 of 6 HAMpatients in group 1 (from 4to2incase 1,from8to6incase2, andfrom4to3 incase3).
In addition, 5 of 5 HAMpatients in group 1 showed decreased spasticity on neurological examination. Bycontrast, motor disability scores did not improve among the HAMpatients in group 2. Also, improvement in spasticity was observed in only 2 of 6 HAMpatients in group 2. Finally, in comparing the 10-m walk times between membersin groups 1 and 2, they were considerably faster in group 1, except for one patient in group 2 (case 8) , who had a markedly elevated level of IL-4 in CSF(change from undetectable to 12.0 pg/ml).
Discussion
The present data indicate that the daily oral administration of 300 mg PTX for 4 weeks in HAMpatients induced an incremental rise in Th2 (IL-4 and IL-10) cytokine levels in both time to walk 10 m before PTXtreatment c: became ambulatory with assistance after PTXtreatment, but was unable to walk before PTXtreatment, d. This case originally had no spasticity. sera and CSF, and conversely a decremental reduction in IFNy (Thl cytokine) levels in sera. These changes coincided with measurable clinical improvement, as previously described (5) . WhenPTX-treated HAMpatients were grouped according to whether or not their levels of IL-4 and IL-10 were elevated, the degree of clinical improvement, as evidenced by decreased spasticity, lower motor disability score and faster10-m walk times, was much higher in the former group. Case 8, who had marked improvement in her 10-m walk time, belonged to the latter group, but her IL-4 level in CSF was markedly elevated following PTXtreatment. Thus, upregulation of Th2 cytokine production appears to account for the clinical improvementin HAMpatients treated with PTX. Moreover, the efficacy of PTX treatment may be based on the correction of the immunological imbalance between Thl and Th2 cytokine responses in HAMpatients. By contrast, the decreased levels of IFN-y in sera of 6 of 12 HAMpatients following PTXtreatment did not correlate with clinical improvement. Wepreviously reported that PTXcauses the downregulation of inflammatory cytokine production, such as TNF-a, IFN-y and GM-CSF,derived from peripheral blood mononuclear cells of HAMpatients (6) . In the present study, PTXtreatment induced decreased levels of IFN-yin the sera of 6 of 12 HAM patients. It is not well understood how PTXregulates the production ofTh2 cytokines, such as IL-4 and IL-10. PTXcauses a nonspecific inhibition of phosphodiesterase, increasing intracellular cyclic AMP (18) . Prostaglandin E2, which also induces the accumulation of intracellular cyclic AMP,inhibits the production of IL-12 (19) , as well as the production ofThl cytokines, such as IL-2 and IFN-y (20) . Therefore, upregulation of Th2 cytokines might be based on downregulation of IL-12 by PTXtreatment. Recently, Rieckmann et al (21) reported that PTXtreatment induces an immunedeviation from Thl to Th2 in patients with multiple sclerosis, an autoimmune disease purportedly caused by a dominant Thl-mediated immune response. Following PTX treatment, mRNAexpression of Th2 cytokines, such as IL-4 and IL-10, in peripheral blood mononuclear cells frommultiple sclerosis patients wasupregulated concomitant with the downregulation of Thl cytokines, such as IFN-y, TNF-aand lymphotoxin, as measured by reverse transcription-polymerase chain reaction.
Overall, our results indicate that upregulation of Th2 cytokine production is related to the degree of clinical improvement in HAMpatients treated with PTX for 4 weeks. In addition, upregulation of Th2 cytokine production might induce the correction of the immunological imbalance of Thl to Th2. Therefore, as in multiple sclerosis, treatments whichfavor the immunedeviation from Thl to Th2 responses might be a beneficial therapeutic strategy for HAMpatients. The development of such treatment modalities warrant critical evaluation.
